Moms, Regulators, Biotech Startups, and the Battle Over a Potentially Life-Saving Drug

Moms, regulators, biotech startups, and the battle over a potentially life-saving drug

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Paul M. Barrett

October 30, 2014 at 10:03 AM UTC

This article is for subscribers only.

This article is part of the November 3, 2014 issue of businessweek.

Moms, Regulators, Biotech Startups, and the Battle Over a Potentially Life-Saving Drug — Leffler's son Aidan was diagnosed with Duchenne in 2006Photograph by Ryan Pfluger

The 2014 World Cup elevated soccer to the top of Aidan Leffler’s roster of obsessions, rivaled only by endangered big cats—especially jaguars, “the coolest”—and Star Wars spaceships. In recognition of his new interest, he’s set up a miniature soccer field with 4-foot-wide goals in his backyard in suburban Bellevue, Wash. “Watch this!” he shouts, preparing to fire a penalty kick.